CancerCare Manitoba is a 3-star charity. It has a B- results reporting grade, which is below average. Its overhead spending is within Ci’s reasonable range and it has reserve funds to cover its program costs for eight years and eleven months.

Founded in 1997, CancerCare Manitoba Foundation (CCMF) fundraises for CancerCare Manitoba (CCMB). CCMB is Manitoba’s provincially mandated agency for cancer and blood disorders. Contributions from CCMF help fund projects that are not eligible for government funding or that funding is not available for. These include prevention, early detection, clinical trials, and research. CCMF reports that all funds raised and donated remain in Manitoba. Since 2000, CCMF has granted over $208m to CCMB. CCMF funds four programs: Patient Experience, Local Research, Clinical Trials, and Prevention, Risk Reduction, and Awareness.

The following program information is from CCMF’s annual report for the fiscal year ending March 2023 (F2023). CCMF’s annual report for F2024 was not available at the time of this update. The program spending breakdown CCMF provides in its annual report does not reconcile with its audited financial statement. Ci reports the percentages for program spending from the F2023 annual report without the dollar values. 

CCMF reported that 48% of its program spending went to Patient Experience in F2023. This program focuses on supporting cancer patients and their families. These include educational resources and after-care programs to help patients. Alongside the Government of Manitoba, CCMF provides funding for a new Centre of Hope at the Western Manitoba Cancer Centre. The new Centre will help patients and families receive the emotional and physical support they need.

CancerCare Manitoba Foundation spent 46% of program spending on Local Research in F2023. CCMB reports that it has over 70 scientists researching cancer and blood disorders. CCMB has three interrelated research disciplines: Basic and Translational Research, Clinical Research, and Health Services Research.

CCMF spent 4% of program spending on Clinical Trials in F2023. Over 1,700 patients at CancerCare Manitoba are currently enrolled in clinical trials. CCMB reports that each year around 300 Manitobans enrol in around 120 clinical trials.

CCMF spent 2% of program spending on Prevention, Risk Reduction, and Awareness in F2023. This program focuses on ensuring access to screening programs and educational tools. The charity reports that if all Manitobans started eating healthy today, 1,300 cancer cases could be prevented in 2038.

In the fiscal year ending March 2024 (F2024), CCMF received $21.3m in donations and special events revenue. CCMF also made $10.3m in investment income (32% of total revenue). Administrative costs are 7% of total revenue (excluding investment income) and fundraising costs are 11% of donations. Overhead spending is 18%, which is within Ci’s reasonable range. For every dollar donated, 82 cents are available for the cause. In F2024, CancerCare Manitoba Foundation granted $11.7m (36% of total revenue) to CancerCare Manitoba.

In F2024, CCMF had a surplus of $16.6m, which is 52% of total revenue, and reported no spending on capital expenditures.

At the end of F2024, CCMF has $103.5m in reserve funds (cash and investments). CCMF has enough reserve funds to cover 888% or eight years and eleven months of its annual program costs.

This charity report is an update that was sent to CancerCare Manitoba Foundation for review. Changes and edits may be forthcoming.

Updated on July 19, 2024 by Thea Clark.